Skip to main content

Table 5 Adverse events (occurring after baseline but before recurrence of parasitaemia in > 2% of children) suspected by investigators to be related to study medication by body weight group

From: Evaluation of the efficacy and safety of artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in Nigerian infants and children

Adverse Events n (%)
  BWG1
5-<10 kg
(N = 50)
BWG2
10-<15 kg
(N = 37)
BWG3
15-<25 kg
(N = 16)
Total
5-<25 kg
(N = 103)
At least one adverse event 30 (60.0) 16 (43.2) 6 (37.5) 52 (50.5)
Anaemia 7 (14.0) 6 (16.2) 1 (6.3) 14 (13.6)
Diarrhoea 5 (10.0) 5 (13.5) 1 (6.3) 11 (10.7)
Clonus 7 (14.0) 5 (13.5) 1 (6.3) 13 (12.6)
Vomiting 7 (14.0) 0 (-) 4 (25.0) 11 (10.7)
Rashes 4 (8.0) 3 (8.1) 0 (-) 7 (6.8)
Hyperreflexia 1 (2.0) 2 (5.4) 1 (6.3) 4 (3.9)
Cough 2 (4.0) 1 (2.7) 0 (-) 3 (2.9)